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Abstract
Chronic kidney disease (CKD) is a major health care problem, affecting more than 35% of the elderly population worldwide.
New interventions to slow or prevent disease progression are urgently needed. Beneficial effects of mesenchymal stem cells
(MSC) have been described, however it is unclear whether the MSCs themselves or their secretome is required. We
hypothesized that MSC-derived conditioned medium (CM) reduces progression of CKD and studied functional and
structural effects in a rat model of established CKD. CKD was induced by 5/6 nephrectomy (SNX) combined with L-NNA
and 6% NaCl diet in Lewis rats. Six weeks after SNX, CKD rats received either 50 mgC Mo r5 0mg non-CM (NCM) twice daily
intravenously for four consecutive days. Six weeks after treatment CM administration was functionally effective: glomerular
filtration rate (inulin clearance) and effective renal plasma flow (PAH clearance) were significantly higher in CM vs. NCM-
treatment. Systolic blood pressure was lower in CM compared to NCM. Proteinuria tended to be lower after CM. Tubular and
glomerular damage were reduced and more glomerular endothelial cells were found after CM. DNA damage repair was
increased after CM. MSC-CM derived exosomes, tested in the same experimental setting, showed no protective effect on the
kidney. In a rat model of established CKD, we demonstrated that administration of MSC-CM has a long-lasting therapeutic
rescue function shown by decreased progression of CKD and reduced hypertension and glomerular injury.
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Introduction
The number of patients with chronic kidney disease (CKD) is
rising to epidemic proportions [1]. In 2008, the median prevalence
of CKD was 7% in persons aged 30 years or older. In persons aged
64 years or older prevalence of CKD varied from 23% to 36% and
is still increasing [2]. The ensuing end-stage kidney disease, as well
as the associated increase in cardiovascular risk, has significant
socio-economic and major public health implications [3]. Nowa-
days, renal replacement therapy consists of either dialysis or,
preferably, kidney transplantation, which is severely limited due to
donor shortage. Both renal replacement strategies are associated
with increased morbidity and mortality [4]. Consequently, new
interventions to slow or prevent CKD progression are being
actively pursued. Mesenchymal stem cell (MSC)-based therapies
have been proposed as potential new treatment modality.
Administration of MSCs has been shown to offer protection in
several models of acute kidney injury [5]. Some data demonstrate
a positive effect of MSC treatment on the loss of renal function in
early stage CKD models as well [6]. In these studies, however,
incorporation and trans-differentiation of injected MSCs were rare
events, suggesting that MSCs primarily have a supportive function,
probably by secreting growth factors and cytokines [7]. Such a
paracrine mode of action has the therapeutic potential for cell-free
treatment strategies using MSC-secreted factors. Importantly, if
administration of MSC-derived secreted factors can reduce CKD
progression, this may have major clinical relevance as such
therapy could overcome problems associated with (allogenic) MSC
administration such as immune incompatibility, MSC maldiffer-
entiation [8,9] and tumorgenicity [10,11]. Thus far, the in vivo
effects of MSC-secreted factors have only been studied in acute
kidney disease. Bi et al. demonstrated that administration of
conditioned medium (CM) from bone marrow-derived MSCs in a
model of acute kidney injury (AKI) increased survival and limited
renal injury, assessed as decreased blood urea nitrogen (BUN)
concentrations [12]. Geishara et al., however, could not confirm
such beneficial effects of MSC-CM in experimental AKI [13].
The relevance of these observations in AKI to CKD is unclear.
To our knowledge, the effect of MSC secreted factors has not been
investigated in a model of established CKD.
The paracrine factors secreted by MSC that are responsible for
the (reno) protective effects have not been fully elucidated. Next to
immunomodulatory and anti-inflammatory properties of MSC,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38746important roles were suggested for proangiogenic factors like
vascular endothelial growth factor (VEGF), hepatocyte growth
factor (HGF) and insulin-like growth factor (IGF) [14–17]. Recent
reports support a central role for microvesicles [18,19] or
exosomes [20] in MSC-mediated tissue repair. In experimental
myocardial infarction the cardio-protective effects of human
embryonic MSC-CM were attributed to exosomes [21,22].
We hypothesized that MSC-secreted factors have a therapeutic
rescue function by supporting renal repair and hence renal
function and thus reduce progression of established CKD.
Therefore, in the setting of established CKD induced by subtotal
nephrectomy, the effects of repeated intravenous delivery of
human embryonic MSC-derived CM on renal hemodynamics and
injury were studied.
Results
CM Treatment Reduces CKD Progression
Six weeks after SNX, CKD was established and rats received
treatment with CM or NCM. At 6 weeks after treatment (12 weeks
after SNX), treatment with CM resulted in significantly higher
GFR and ERPF compared to treatment with NCM (both p,0.05)
at t=12 weeks (figure 1). No differences were observed in
hematocrit, mean arterial pressure (MAP), renal vascular resis-
tance (RVR), filtration fraction (FF) and fractional excretion of
sodium and potassium between CM and NCM (table 1). We
observed no significant differences in GFR and ERPF in healthy
controls between CM and NCM treatment. Exosome treatment
had no effect on CKD progression (table S1).
CM Treatment Reduces the Increase of Systolic Blood
Pressure (SBP) in CKD Rats
CKD animals showed significant hypertension compared to
healthy controls (figure 2a). SBP was significantly lower in CKD-
CM treated rats compared to CKD-NCM treated rats at week 11
(146617 vs. 163621 mm Hg; p,0.05, figure 2a). CKD rats
showed more proteinuria compared to healthy controls. Protein
excretion tended to be lower in CKD-CM-treated compared to
CKD-NCM-treated rats (figure 2b; p=0.071). No differences were
observed in urea and creatinine clearance between CKD-CM and
CKD-NCM rats at wk 11 (table 2). Plasma creatinine was
increased in CKD-NCM compared to CKD-CM (p=0.05).
Importantly, CM or NCM administration did not influence
SBP, proteinuria or creatinine clearance in healthy control rats.
Exosome treatment had no effect of SBP (table S2).
CM Increases the Number of Glomerular Endothelial Cells
and Reduces Glomerulosclerosis and Tubular Damage in
CKD Rats
The percentage of glomerular endothelial cells, (JG12 positive),
was significantly higher in CKD-CM compared to CKD-NCM-
treated rats (p,0.05, fig. 3). Both CKD-CM and CKD-NCM-
treated rats showed marked glomerulosclerosis as compared to
healthy rats with respectively 31% and 26% normal, non-sclerotic
glomeruli as compared to more than 85% normal glomeruli in
healthy controls. Comparing the number of partly and totally
sclerotic glomeruli between the CKD groups reveals a favourable
shift with significantly more partly sclerotic glomeruli and less
totally sclerotic glomeruli in CKD-CM compared to CKD-NCM-
treated rats (figure 4). DNA damage and repair was measured by
induction of cellular c-H2AX; c-H2AX expression has been
Table 1. Terminal kidney function measurements.
2K-NCM n=6 2K-CM n=6 CKD-NCM n=13 CKD-CM n=13
Body weight (g) 442643 432623 364622* 355616*
MAP (mm Hg) 99699 3 613 122622* 135619*
RBF (ml/min/100 g) 4.6461.37 5.2260.66 2.1060.49* 2.5660.43*
RVR (mm Hg/ml/min) 4.961.1 4.160.6 1769* 1564*
Hematocrit 50614 9 624 5 62* 4662*
FF 0.3260.03 0.3060.05 0.2860.05 0.2960.05
FeNa (%) 0.4460.24 0.3860.24 1.5961.79* 1.5560.77*
FeK (%) 13661 4 663 8 611* 45613*
Mean6SD *P,0.05: 2K vs. CKD.
MAP=mean arterial pressure. RBF=renal blood flow. RVR=renal vascular resistance. FF=filtration fraction. FeNa=fractional excretion of sodium. FeK=fractional
excretion of potassium.
doi:10.1371/journal.pone.0038746.t001
Figure 1. CM treatment increases kidney function. CM treatment
increased glomerular filtration rate (GFR) (A) and effective renal plasma
flow (ERPF) (B) in CKD. 2K-NCM (n=6); 2K-CM (n=6); CKD-CM (n=13);
CKD-NCM (n=13). Post-hoc test p-value is shown.
doi:10.1371/journal.pone.0038746.g001
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tissue damage and induction of DNA damage repair [23,24]. We
noted with interest that CM significantly increased glomerular c-
H2AX induction in CKD rats compared to healthy rats whereas
CKD-NCM rats were not different compared to healthy rats
(figure 5). The numbers of glomerular proliferating cells as
determined by Ki67 and glomerular inflammatory CD3
+ and
ED-1
+ cells were not different between the CKD-CM and CKD-
NCM -treated rats (table 3).
Compared to healthy rats, both CKD-NCM and CKD-CM-
treated rats demonstrated enhanced tubulo-interstitial damage.
However, tubular atrophy and interstitial fibrosis were significantly
lower after CM treatment in CKD rats (figure 6). Tubular
deposition of collagen I and III was decreased in CKD-CM rats
compared to CKD-NCM rats (figure 7).
Thenumberofendothelialcellspertubularfieldwasnotdifferent




cells was not different in glomeruli and tubulo-interstitium of CM
and NCM as determined by TUNEL staining (table 3). Exosome
treatment had no effect of renal damage (figure S1).
Cytokine Profile in Remnant Kidney is Altered after CM
Treatment
To screen whether CM affected local production of inflamma-
tory cytokines by kidney cells in healthy and CKD kidneys, a
cytokine array was performed on kidney homogenates (figure 8a).
Seven inflammatory cytokines, Monokine Induced by Gamma-
Interferon (MIG); Macrophage Inflammatory Protein-1 alpha
(MIP1a); Macrophage Inflammatory Protein-3 alpha (MIP3a);
thymus chemokine, Tissue Inhibitor of Metalloproteinase-1
(TIMP-1); VEGF and Interleukin 1 Receptor Antagonist (IL1-
RA) were only detected in CKD and not in healthy kidneys.
Fractalkine and Regulated upon Activation, Normal T-cell
Expressed, and Secreted (RANTES) were lower in CKD kidneys,
whereas L-selectin was higher in CKD kidneys compared to
healthy kidneys. In healthy kidneys CM had no significant effects
on cytokines, whereas in CKD kidneys CM increased the
expression of both Fractalkine and IL-1Ra. Gene expression of
Fractalkine was decreased in CKD compared to healthy controls
and increased by CM in CKD (figure 8b).
CM Effectively Induces Angiogenesis and Wound Closure
To evaluate the effectiveness of CM in vitro, an angiogenesis
assay and wound closure assay were performed. CM was able to
significantly induce angiogenesis compared to NCM (figure 9a).
Exosome treatment showed also increased angiogenesis (figure S2).
We also analysed the effect of CM on wound closure in an in vitro
scratch wound assay. As PBS induces cell death in the scratch
wound assay, PBS could not be used as vehicle or control. We
therefore used CM and NCM diluted in DMEM. CM-treated
HMECs showed increased wound closure compared to NCM
treatment (figure 9b).
Figure 2. CM treatment decreased systolic blood pressure (A)
and proteinuria (B) in CKD. 2K-NCM (n=6); ¤ 2K-CM (n=6); &
CKD-CM (n=13);N CKD-NCM (n=13). *P,0.05: CKD vs. 2K, { P,0.05:
CKD-CM vs. CKD-NCM.
doi:10.1371/journal.pone.0038746.g002
Table 2. Longitudinal measurements after CM treatment at week 6 after SNX.
2K-NCM n=6 2K-CM n=6 CKD-NCM n=13 CKD-CM n=13 P (CKD-CM vs. CKD-NCM)
Urea (mmol/L)
wk 5 5.760.9 6.261.0 10.362.4* 10.262.5* 0.854
wk 9 5.960.5 5.961.1 10.862.2* 12.261.9* 0.058
wk 11 6.560.8 6.961.5 9.761.9* 9.961.8* 0.701
Plasma creatinine (mmol/L)
wk 5 20.163.3 20.861.1 49.768.8* 48.669.9* 0.948
wk9 21.866.6 25.664.5 44.9611.4* 42.966.6* 0.558
wk11 28.967.5 22.763.1 51.0614.2* 42.866.9* 0.050
Creatinine clearance (ml/min)
wk 5 4.1860.52 4.1361.31 1.1860.22* 1.1360.25* 0.795
wk 9 3.8461.27 3.0060.44* 1.4860.36* 1.4360.21* 0.801
wk 11 2.8460.74 3.2760.93 1.3260.35* 1.5060.28* 0.386
Week numbers indicate the week after SNX. Week 5 represents the week before treatment.
*P,0.05 vs. respective 2K controls. Posthoc p-value is shown.
doi:10.1371/journal.pone.0038746.t002
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Our study demonstrates for the first time that repeated IV
administration of human embryonic MSC derived CM as a
‘rescue intervention’– i.e. 6 weeks after CKD induction - can
markedly attenuate the reduction of both GFR and ERPF as
assessed by classical ‘‘gold standard’’ inulin and PAH clearance
methodology and that this effect is detectable at 6 weeks after
administration indicating long-term protection. Furthermore,
histology showed a reduction in renal injury.
Previous studies showed beneficial effects of MSC administra-
tion in models of AKI (reviewed in [5,7]) and have even led to
phase I clinical trials on allogenic MSC administration in AKI
(clinicaltrial.gov Identifier: NCT00733876 and NCT01275612).
Figure 3. CM treatment increased the number of glomerular endothelial cells (A, C-D), but did not increase tubular endothelial cell
number (B, E-F) shown by a JG12 staining. 2K-NCM (n=6); 2K-CM (n=6); CKD-NCM (n=13); CKD-CM (n=13). *P,0.05: CKD vs. 2K, {P,0.05:
CKD-CM vs. CKD-NCM.
doi:10.1371/journal.pone.0038746.g003
Figure 4. Glomerulosclerosis was reduced by CM treatment. On PAS-stained sections, glomeurosclerosis was reduced after CM treatment (A).
Normal (B), segmental (C) and totally sclerotic are shown (D). Black arrows indicate sclerotic areas. 2K-NCM (n=6); 2K-CM (n=6); CKD-NCM (n=13);
CKD-CM (n=13). *P,0.05: CKD vs. 2K, {P,0.05: CKD-CM vs. CKD-NCM.
doi:10.1371/journal.pone.0038746.g004
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unclear and data on MSC administration in CKD are sparse. In a
few studies, administration of MSC was shown to prevent
development of CKD if administered directly after induction of
the disease [6,25–28] or at early stages of CKD [29]. However,
studies aiming at therapeutic ‘rescue’ in established CKD have not
been reported. Furthermore, although most of the reports on
beneficial effects suggest that the therapeutic effect is at least in
part mediated by paracrine factors secreted by the cells [30], only
two studies have applied MSC-CM as therapeutic strategy, and
both were performed in AKI models and report conflicting results
[12,13]. More recently, two studies reported beneficial effects of
microvesicles derived from human adult MSC-CM in experimen-
tal AKI [18,19].
We intravenously administered human embryonic MSC-CM
that was harvested using a clinically compliant protocol. We used
the 5/6
th nephrectomy ablation model, a known experimental
model of progressive renal disease, associated with systemic and
glomerular hypertension, capillary loss, renal inflammation and
gradual development of glomerulosclerosis, resembling human
CKD [31,32]. Creatinine clearance tends to underestimate the
decline in GFR due to extensive tubular creatinine secretion in rats
[33], underlining the importance of the gold standard method to
determine renal function by inulin and PAH clearance [34]. We
previously showed a marked reduction of GFR and ERPF in this
model using classic clearance technology, while this was less
apparent from changes in plasma creatinine, plasma urea, or
creatinine clearance [35]. Injection of CM IV at 6 weeks after
induction of CKD, a time point at which kidney failure is
established, resulted in a long-term beneficial effect on GFR and
ERPF as well as a marked reduction in SBP of up to 27 mmHg,
lasting up to at least six weeks post-injection between groups.
Besides these functional effects, glomerulosclerosis was reduced
and glomerular DNA damage repair increased. Our findings of a
beneficial effect of human embryonic MSC secretions on
progression of experimental established CKD may have relevance
for treatment of human CKD. Clinical use of cell-free MSC
secretions may have important advantages over MSC administra-
tion, for example with regard to risks of malignant [10,11] or non-
malignant transdifferentiation [8,9].
Figure 5. CM treatment increased DNA damage repair. After logarithmic transformation, more c-H2AX positive cells, indicating glomerular
nuclei undergoing DNA damage repair, were found after CM treatment in CKD (A). Black arrow indicates positive nucleus (B). 2K-NCM (n=6); 2K-CM
(n=6); CKD-NCM (n=13); CKD-CM (n=13). *P,0.05: CKD vs. 2K.
doi:10.1371/journal.pone.0038746.g005
Table 3. Renal morphology.
2K-NCM n=6 2K-CM n=6 CKD-NCM n=13 CKD-CM n=13
Glomerular measurements
Ki 67
+ cells/glomerulus 3.8561.01 4.1761.38 5.1161.52 5.9961.60*
ED1
+ cells/glomerulus 1.3360.51 1.3360.51 2.7061.34* 2.5960.84*
CD3
+ cells/glomerulus 0.1460.08 0.0960.07 0.4660.36* 0.3460.13
Tubular measurements
ED1
+ cells/tubular field 12.760.8 13.563.5 32.9610.2* 34.363.9*
CD3
+ cells/20 tubular fields 2.260.9 1.460.7 49.3623.7* 48.868.0*
TUNEL
+cells/tubular field 0.6560.68 0.2360.14 1.7561.12 1.3060.77*
Mean6SD. *P,0.05: 2K vs. CKD;
doi:10.1371/journal.pone.0038746.t003
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effects of paracrine factors secreted by MSC on the injured kidney:
immunosuppressive and inflammatory actions, proangiogenic,
antifibrotic and anti-apoptotic effects. Our data points at
enhanced glomerular endothelial regeneration and genome
integrity preservation through active DNA damage signaling.
Such enhancement of glomerular endothelial repair has previously
been shown to provide protection against glomerulosclerosis
progression [36]. We observed a favorable shift in glomeruloscle-
rosis after CM as compared to NCM treatment, which was
associated with higher glomerular endothelial cell numbers after
CM, whereas glomerular size was not different. Approximately
10% fewer glomeruli were totally sclerotic hence non-functional in
CKD-CM rats which match the increase of GFR compared to
CKD-NCM rats. The constant filtration fraction points at
increased preglomerular and intraglomerular vascular capacity,
possibly by preserved endothelial function.
Figure 6. Tubulo-interstitial damage on PAS-stained sections was reduced after CM treatment in CKD rats. CM treatment decreased
tubular fibrosis and atrophy (A). Differences between CKD (B) and healthy (C) tubular kidney tissue are shown. White arrow indicates infitration, black
arrows showing proteincasts. 2K-NCM (n=6); 2K-CM (n=6); CKD-NCM (n=13); CKD-CM (n=13). *P,0.05: CKD vs. 2K, {P,0.05: CKD-CM vs. CKD-NCM.
doi:10.1371/journal.pone.0038746.g006
Figure 7. Tubular collagen I and III deposition was reduced after CM treatment in CKD rats. CM treatment reduced sirius red staining (A).
Raw (B) and polarized (C) pictures are shown. 2K-NCM (n=6); 2K-CM (n=6); CKD-NCM (n=13); CKD-CM (n=13). *P,0.05: CKD vs. 2K, {P,0.05: CKD-
CM vs. CKD-NCM.
doi:10.1371/journal.pone.0038746.g007
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enhanced endothelial cell migration and angiogenesis in vitro.
These observations are in line with a report by Togel et al
demonstrating in vitro vasculotropic effects of adult rat MSC CM
[15]. Recently, our human embryonic MSC-CM was also shown
to increase capillary density and improve cardiac function after
acute myocardial infarction in a pig model [22]. In our CKD
model, at 6 weeks after injection of MSC-CM or MSC-NCM we
found no differences in the numbers of apoptotic and proliferating
cells, nor in the presence of VEGF in the kidney, however, we
Figure 8. Inflammatory cytokine expression in healthy and CKD kidneys. A: Cytokine array in array. Striped bars=2K-CM (n=6); dotted
bars=2K-NCM (n=6); black bars=CKD-NCM (n=7); white bars=CKD-CM (n=4). IL-8=interleukin 8; sICAM=soluble Inter-Cellular Adhesion
Molecule; L-selectin=leucocyte cell-adhesion molecule; RANTES=Regulated upon Activation, Normal T-cell Expressed, and Secreted; MIG=Mono-
kine Induced by Gamma-Interferon; MIP1a=Macrophage Inflammatory Protein-1 alpha; MIP3a=Macrophage Inflammatory Protein-3 alpha; Timp-
1=Tissue Inhibitor of Metalloproteinase 1; VEGF=Vascular Endothelial Growth Factor; IL-1RA=Interleukin 1 Receptor Antagonist. B: Fractalkine
mRNA in healthy and CKD kidneys. Striped bars=2K-CM (n=6); dotted bars=2K-NCM (n=6); black bars=CKD-NCM (n=7); white bars=CKD-
CM (n=4). *P,0.05: CKD vs. 2K.
doi:10.1371/journal.pone.0038746.g008
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have occurred in an earlier stage. We did observe a reduction in
tubular inflammation and fibrosis as well as increased expression
of fractalkine and Il-1RA, two cytokines that are involved in
recruitment of inflammatory response [37,38] after CM as
compared to NCM treatment, suggesting a role for paracrine
anti-inflammatory and anti-fibrotic effects, consistent with findings
in other disease models [39,40].
Recent studies on the effects of MSC-derived microvesicles in
acute kidney injury models support a potential exosome-mediated
renoprotective effect. Bruno et al. reported that human adult
MSC-derived microvesicles, which include exosomes, mimicked
the protection against AKI as provided by intravenously
administered MSC [18]. Gatti et al showed that single adminis-
tration of human MSC-derived microvesicles immediately after
ischemia-reperfusion injury protected against the development of
both acute and chronic kidney injury [19]. Furthermore, in a
mouse myocardial infarction model it was recently shown that
cardioprotection by human embryonic MSC was mediated by
exosomes [21]. Based on the above reports we proposed exosomes
to be the CM components that provide protection against CKD
progression. However, repeated IV administration of human
embryonic MSC derived exosomes in our model of established
CKD did not affect progression of CKD (text S1).
We used exosome concentrations in CKD rats that were
approximately fourfold the concentration of exosomes present in
CM, similar to the exosome concentrations previously shown to
improve cardiac function after myocardial infarction [21].
Moreover, in vitro both human embryonic MSC derived exosomes
and CM effectively induced wound closure and angiogenesis. Lack
of a significant therapeutic effect of exosomes in this model of
chronic renal injury may be due to tissue specific requirements
regarding exosome content and/or dose. Our results suggest that
the beneficial effect in our model of CKD was mediated by soluble
factors and cytokines. Whether rat exosomes would be more
effective in the damaged kidney is unknown.
In line with an effect via soluble factors and cytokine, Togel et
al. demonstrated that adult rat MSC-CM contains VEGF, HGF
and IGF [15] which mediate renoprotection. Previous analysis on
the secretory product of human embryonic MSC showed the
presence of several gene products that play a role in angiogenesis;
kinase insert domain receptor, VEGF, interleukin 8, angiopoietin
and fibroblast growth factor [41]. Studies showing that MSC with
knockdown of IGF-1 or VEGF failed to protect rats from AKI
[14,16] support a role for proangiogenic factors. Semedo et al.
found higher levels of anti-inflammatory cytokines in kidney
extracts of MSC-treated animals after ischemia reperfusion injury
[29], which is consistent with our observations 6 weeks after CM
administration in CKD.
A limitation of our study is that we did not administer CM
depleted of exosomes in our CKD model. Therefore we cannot
exclude that exosomes mediate the beneficial effect in CKD but
need an immunomodulatory or anti-inflammatory factor that is
present in the CM. In this respect a recent study may be of interest
which reported that porcine MSC have limited immune-modu-
lating activity which abolishes their protective efficacy in AKI
[42].
In conclusion, our study demonstrates a marked renoprotec-
tive effect of human embryonic MSC derived CM in a rat
model with established CKD, as shown by a higher GFR and
considerably less glomerular damage after a CM administration.
This is probably due to increased endothelial cell regeneration
Figure 9. CM stimulates in vitro angiogenesis (A) and wound closure (B). Average tube length was increased after CM treatment compared
to NCM (C+D). In a scratch wound assay, CM treatment increased wound (indicated by black arrow in E) closure compared to NCM treatment.
*P,0.05 CM vs. NCM.
doi:10.1371/journal.pone.0038746.g009
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genesis. These findings provide a basis for further research




Ethics Statement. The protocol was approved by the
Utrecht University committee of Animal Experiments (DEC nr
2007.II.050.131).
Animal model. Male inbred Lewis rats (Charles River,
Sulzfeld, Germany) were housed under standard conditions in a
light-, temperature- and humidity-controlled environment.
CKD was induced in 8-week-old inbred male Lewis rats by two-
stage subtotal nephrectomy (SNX) as described (t=0) [43]. Briefly,
the right kidney was removed (wk –1) and one week later (wk 0) the
poles of the left kidney were cut off, equalling approximately 66+/
24% of the weight of the previously removed kidney. Progression
of CKD was accelerated with L-N
G-Nitroarginine (L-NNA), a
nitric oxide (NO)-synthase inhibitor (20 mg/L) in drinking water
for 8 wk, (wk 24 to wk 4), and after wk 0, animals were fed
standard powdered chow (CRM-FG; Special Diet Services Ltd.,
Witham, Essex, UK) supplemented with 6% NaCl.
MSC-CM Preparation
The protocols for MSC generation and CM preparation have
been described previously [41]. In short, a chemically defined
serum free culture medium (Dulbecco’s modified eagle medium
(DMEM), supplemented with insulin, transferrin, and selenopro-
tein, fibroblast growth factor 2, platelet derived growth factor AB,
glutamine-penicillin-streptomycin, and ß-mercapto-ethanol) was
conditioned by MSCs derived from human embryonic stem cells
(hESCs) using a clinically compliant protocol. Three polyclonal,
karyotypically stable and phenotypically MSC-like cultures that
did not express pluripotency-associated markers but displayed









2) and gene expression profile, were
generated by trypsinization and propagation of hESCs from either
HuES9 hESC line or H1 hESC line in feeder- and serum-free
selection media [44]. One of these cultures, HuES9.E1 could be
stably expanded for at least 80 population doublings. To harvest
MSC secretions, hESC-derived MSC cultures were transferred to
a chemically defined, serum free culture medium to condition the
medium for three days before the media containing MSC
secretions were collected, clarified by centrifugation, concentrated
25 times using 10 kDa MW cut-off ultra-filtration membranes and
sterilized by filtration through a 220 nm filter. After these steps,
the protein concentration was 0.50 mg/ml. As a negative control,
the above-mentioned serum free culture medium was processed
equally (non-conditioned medium, NCM). To study the effect of
MSC-specific proteins, CM and NCM were diluted in sterile PBS
in parallel before administration to reach a protein concentration
of 50 mg/250 ml. For MSC-derived exosomes preparation, see text
S1.
Effects of Administration of MSC-derived Conditioned
Medium in CKD Rats
At week 5 rats with confirmed CKD were stratified based on
plasma urea (.9 mmol/L) and systolic blood pressure (SBP) to
receive CM or NCM via tail vein injections (twice daily for 4
consecutive days) at week 6 when stable CKD has developed, as
follows: healthy-NCM (n=6), healthy rats received 250 ml NCM
per injection; healthy-CM (n=6), healthy rats received 250 ml
CM per injection; CKD-NCM (n=13), rats with CKD received
250 ml NCM per injection; CKD-CM (n=13), rats with CKD
received 250 ml NCM per injection.
At week 12 terminal kidney function was measured under
barbiturate anesthesia (see below). Directly thereafter, rats were
sacrificed and tissues were collected and either frozen in liquid
nitrogen or fixed in 4% paraformaldehyde (PFA) for embedding in
paraffin. For detailed time-line, see figure 10. MSC-derived
exosomes were studied in the same experimental set-up (text S1).
Longitudinal Chronic Kidney Disease Evaluation
Rats were weighed weekly. In week 5, 9 and 11, 24 h urine,
blood samples were collected and SBP was measured by tail cuff
sphygmomanometry [45]. To collect 24 h urine, rats were placed
in metabolism cages without food for 24 h, but with free access to
water with 2% glucose. Urine was collected on antibiotic/
antimycotic solution (Sigma, St. Louis, MO; A5955) and stored
at –80uC. Blood samples were collected from the tail vein. Urine
protein was measured with Coomassie blue. Sodium and
potassium were determined by flame photometry.
Terminal Kidney Function
Kidney function was assessed by inulin clearance to
determine glomerular filtration rate (GFR) and para-ammino
hippuric acid (PAH) clearance to determine the effective renal
plasma flow (ERPF) as described [45]. Briefly, rats were
anesthetized with intraperitoneal pentobarbital sodium (60 mg/
kg) and placed on a servo-controlled surgical table that
maintained body temperature at 37uC. The trachea was
cannulated with a PE-10 cathether. A PE-50 catheter was
placed in the left jugular vein for infusion of solutions and a
PE-10 catheter was introduced in this PE-50 cathether for
supplemental anesthetic. The left femoral artery was cannulated
with PE-50 tubing for measurement of mean arterial pressure
(MAP) and blood sampling. A PE-50 catheter was placed in the
bladder for urine collection. During surgery, animals received
an intravenous infusion of a 150 mM NaCl solution containing
6% bovine serum albumin (BSA). Following surgery, the
infusion was switched to a 150 mM NaCl solution with 1%
BSA at the same infusion rate. This infusion was maintained
throughout the experiment. The solution also contained inulin
and para-amino hippurate (PAH) for clearance measurements.
A 60-min equilibration period was observed before the start of
the 60-min clearance measurements. During this clearance
measurement urine was sampled for 15 minute periods and
before and after the clearance measurement blood was sampled.
Clearances and fractional excretions were calculated by
standard formulae. Renal blood flow was calculated from ERPF
and hematocrit.
Renal Morphology
Glomerulosclerosis and tubular interstitial damage were
scored on 3 mm periodic acid Schiff (PAS)-stained paraffin-
embedded slides [46]. Collagen I and III contents was stained
with Sirius red, visualized with circular polarized light and
digitally analyzed using ImageJ software [46]. The percentage of
collagen area was calculated by dividing the Sirius red stained
area by the total image area. Monocytes/macrophages (ED-1
stain) and leucocytes (CD3 stain) were counted in glomeruli and
tubulo-interstitum [47]. Terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end labeling (TUNEL) staining
(Apoptag Plus in situ Peroxidase kit, Millipore, Temecula, CA,
USA) was performed according to manufacturer guidelines. The
number of apoptotic cells was determined as the number of
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fields (x200 magnification) per section. Endothelial cells were
stained with JG12 (Bender Medsystems GmbH, Vienne, Austria)
after heat antigen retrieval in citrate buffer (pH 6.0) [48]. JG12
positive cells were determined in the glomeruli (calculated in at
least 100 glomeruli per animal) and in peritubular areas
(calculated in 20 peritubular fields per animals) using Adobe
Photoshop software, version 8.0.1 (Adobe Systems; San Jose,
CA) and ImageJ software, version 1.42q (National Institutes of
Health; Bethesda, MD). To score nuclei repairing DNA
damage, paraffin-embedded kidney sections were deparafinized
and treated with PO block for 15 minutes and incubated at
100uC in Citrate/HCL buffer for 20 minutes. The sections were
stained with mouse anti-cH2AX (ser139) (Millipore, 1:200)
overnight at 4uC. Polyclonal rabbit anti-mouse HRP (Dako,
1:100) was incubated 30 minutes at RT. Finally, BrightVision
Poly HRP-Anti Rabbit IgG (Immunologic) was incubated for 1
hour RT. Nova RED substrate kit for Peroxidase (Vector, SK-
4800) was used and counterstained with hematoxyline. Analysis
was performed using the Aperio ImageScope software.
Cytokine Array and Gene Expression in Renal Tissue
Kidney samples were collected at termination (6 weeks after
CM or NCM administration) and quickly frozen in liquid
nitrogen. A rat cytokine array (R&D systems) was performed on
kidney homogenates according to manufacturer’s instructions to
screen whether CM treatment stimulated local secretion of specific
inflammatory cytokines by the host kidney cells. Samples were
pooled per treatment group and equal amounts of protein were
loaded on the blots. From all pooled samples blots were performed
in duplicate and averages of these two pixel densities were used to
calculate the average density with Image J software. Background
staining and spot size were analysed as recommended by the
manufacturer. Briefly, pictures were converted to 8-bit inverted
jpeg files and spots were encircled. Per blot, equal spot sizes were
analysed.
To determine whether a local production of cytokines could be
confirmed on mRNA level, cDNA was isolated from frozen
remnant kidney tissue and expression of fractalkine was deter-
mined using quantitative real-time RT-PCR (ABi PRiSM
790Sequence Detection SYStem, applied Biosystems, Foster City,
CA). The following TaqManH Gene Expression Assays (Applied
Biosystems) were used: (fractalkine (CX3CL1): Rn00593186_m1),
(ß-actin: Rn00667869_m1) and (calnexin: Rn00596877_m1).
Reactions were carried out in duplicate. Cycle time (Ct) values
for fractalkine were normalized for mean Ct-values of Calnexin
and b-actin, which we previously determined to be the two most
stable housekeeping genes across all groups using the geNorm-
program (http://medgen.ugent.be/,jvdesomp/genorm/), and
expressed relative to a calibrator (the sample with the lowest
expression: the 2K controls), using the DDCt-method. Hence,
steady state mRNA levels were expressed as n-fold difference
relative to the calibrator.
In vitro Angiogenesis Assay
The potential of CM to stimulate angiogenic tube formation
was assessed in vitro. For this, 10 ml matrigel (Millipore, Temecula,
CA, USA) was added in the inner compartment of an ibidi m-
angiogenesis slide (Ibidi, Munchen, Germany). After the matrigel
had solidified, 50 ml of tests-suspension was added, containing
respectively 10 mgC Mo r1 0 mg NCM. Subsequently, 10 ml
unsupplemented MCDB medium containing 10.000 trypsinized
human microvascular endothelial cells (HMEC-1) cells (HMECs;
Centers for Disease Control and Prevention, Atlanta, USA) was
added. The angiogenesis area was photographed using light
microscopy after 18 hours incubation at 37uC, 5% CO2 and the
mean tubule length, used as a measure of angiogenesis, was
determined using Angioquant software [49]. Each sample was
assayed in triplicate. The angiogenic potential of MSC-derived
exomes was also studied (see text S1).
In vitro Scratch Wound Assay
The potential of CM to stimulate endothelial cell migration was
assessed by in vitro scratch wound assay. A mechanical scratch was
created with a pipet tip in a confluent monolayer of HMECs. After
washing with PBS, 200 ml DMEM medium containing respec-
tively 40 mgC Mo r4 0mg NCM was placed on the cells. DMEM
without supplementation served as control. Reference lines were
made on the bottom of the wells to obtain exactly the same field
during image acquisition. The scratched area was photographed
using light microscopy at start and after 6 hours incubation (37u).
The extent of closure after 6 hours was determined relative to the
starting width of the scratch (Image-Pro plus software, Media
Cybernetics 3.0). Each sample was measured in two wells and two
Figure 10. Representation of experimental set up. UNX=uninephrectomy; SNX=subtotal nephrectomy; CM=conditioned medium
administration. Stars indicate longitudinal measurements.
doi:10.1371/journal.pone.0038746.g010
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analysis.
Statistical Analyses
Data are presented as mean 6 standard deviation and analyzed
by analysis of variance (One-way ANOVA with a Newman-Keuls
post-test, Two-way ANOVA with a Newman-Keuls post-test) or
Student’s T-test, where appropriate. P,0.05 was considered
significant.
Supporting Information
Figure S1 Glomerulosclerosis and tubulo-interstitial
damage after exosome treatment. A: Segmental (segm)
and total (tot) glomerulosclerosis (GS); B: Tubulo-
interstitial damage. Exosomes (n=8); PBS (n=7). There were
no significant differences.
(TIF)
Figure S2 Exosomes stimulates in vitro angiogenesis.
Average tube length was increased after exosome treatment
compared to PBS. *P,0.05: exosomes vs. PBS
(TIF)
Table S1 Terminal kidney function measurements in
the exosome and PBS groups. There were no significant
differences.
(DOCX)
Table S2 Longitudinal measurements after exosome
treatment at week 6 after SNX. Week numbers indicate the
week after SNX. Week 5 represents the week before treatment.
There were no significant differences.
(DOCX)
Text S1 Supporting text including materials and meth-
ods, results and references.
(DOCX)
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